Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
Yong‐Chen Lu
High Impact
Assistant Professor (Tenure Track)
Also affiliated: Ontario Institute for Cancer Research (2007–2011); Centers for Disease Control and Prevention (2013); National Institutes of Health (2013–2023); University Health Network (2007–2011); National Yang Ming Chiao Tung University (2014); Bristol-Myers Squibb (Germany) (2017); University of Toronto (2007–2009); Princess Margaret Cancer Centre (2022); Data Harbor (United States) (2015); Palmetto Hematology Oncology (1995); Phio Pharmaceuticals (United States) (2017); Winthrop Rockefeller Foundation (2021–2025); Institute of Biophysics (2009); National Cancer Institute (2013–2023); ORCID (2021); Center for Cancer Research (2017–2022); California State University, Long Beach (2021); Xiaomi (China) (2017); University of Colorado Denver (2009); National Yang Ming Chiao Tung University (2014)
Faculty Researcher
Pathology, College of Medicine
28 h-index
90 pubs
12,649 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Yong‐Chen Lu's research focuses on understanding and manipulating T-cell responses in the context of cancer immunotherapy. His work investigates the molecular signatures of T cells that recognize tumor-specific antigens, known as neoantigens. Lu has published research on the direct identification of neoantigen-specific T-cell receptors (TCRs) from tumor specimens using high-throughput single-cell sequencing, a technique that is crucial for studying T-cell biology and developing cancer therapies.
His group studies adoptive cellular therapy, including the use of autologous tumor-infiltrating lymphocytes and TCR-engineered T cells. Recent publications explore the potential of liquid biopsies in hepatocellular carcinoma for immunotherapy and the identification of neoantigen-reactive T lymphocytes in various human cancers, such as glioblastoma. Lu also investigates the role of specific molecules, such as TREM-2, in mediating immune responses that can impact chronic diseases.
Lu leads a research group and has collaborated with researchers at the University of Arkansas for Medical Sciences, including Charles M. Quick, Mayumi Nakagawa, Hannah Coleman, and Takeo Shibata, with whom he shares multiple publications. His work is recognized with a high h-index of 28 and over 12,000 citations.
Metrics
- h-index: 28
- Publications: 90
- Citations: 12,649
Selected Publications
-
Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Isolation of mitochondrial mutation-specific T cell receptors (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation (2025)
-
376 Inhibition of GSK3β-mediated 53BP1 T334 phosphorylation in T cells enhances infiltration and cytotoxicity against head and neck squamous cell carcinoma (2024)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Deciphering CD4<sup>+</sup> T cell‐mediated responses against cancer (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- Developing T cell-based immunotherapy targeting breast cancer antigen FBXO39 ABCRP Principal Investigator
- Developing CD4 T cell-based immunotherapy for breast cancer ABCRP Principal Investigator
- Defining tumor infiltrating B cells and their role in the modulation of TIL immunotherapy The Mark Foundation for Cancer Research via H Lee Moffitt Cancer Center & Research Institute Co-Investigator
- A pilot study of developing T cell-based cancer immunotherapies for African American and Hispanic populations TRI Principal Investigator
Collaboration Network
Top Collaborators
Teresa Evans
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Charles M. Quick
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Isolation of mitochondrial mutation-specific T cell receptors
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure
Anna Pasetto
Oslo University Hospital (NO)
4 shared publications
- Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
- Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
- Editorial: Personalized immunotherapy for cancer
- Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
Takeo Shibata
Kanazawa Medical University
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Hannah Coleman
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Mayumi Nakagawa
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Jasmine Crane
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
David W. Ussery
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Sumit K. Shah
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Steven R. Post
University of Arkansas Medical Center
3 shared publications
In database
- Isolation of mitochondrial mutation-specific T cell receptors
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients
- Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
William W. Greenfield
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Similar Researchers
Based on overlapping research topics
Latambria Hampton
University of Arkansas for Medical Sciences
Immune Cell Function and Interaction
T-cell and B-cell Immunology
Molecular Biology Techniques and Applications
Katie R. Ryan
University of Arkansas for Medical Sciences
Molecular Biology Techniques and Applications
Cancer Cells and Metastasis
Receptor Mechanisms and Signaling
Lauren Eads
University of Arkansas for Medical Sciences
Molecular Biology Techniques and Applications
Cancer Cells and Metastasis
Cancer-related molecular mechanisms research
Lindsey Clark
University of Arkansas for Medical Sciences
Molecular Biology Techniques and Applications
Cancer Cells and Metastasis
Cancer-related molecular mechanisms research
Yuntao Dai
University of Arkansas at Fayetteville
Molecular Biology Techniques and Applications
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Martin J. Cannon
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Cell Function and Interaction
Cancer-related molecular mechanisms research